duce a feelinig of well being in debited[1] patients.

Marketing of tranquilizers with Vitamins

2123. SHRI M. KADHARSHA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a;) whether it is a fact that combination of Tranquilizers with Vitamins are allowed for marketing in the country;

(b) what are the basis o_n which such combinations have been cleared for marketing and what are the rational for such combinations;

(c) whether $_{anv}$ trial o_n these combinations wer_e done;

(d) if so, what are the side effects and advantage of this combination over single drug formulations;

(e) the names of leading brands being marketed in th_e country along with names of manufacturers; and

(f) what are the diseases for which such combinations ar_e used?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE); *W* Yes, Sir.

(b) to (d) The formulations containing tranquillizers and vitamins were licensed more than a decade ago by the State Licensing Authorities, at a time when th,* criteria for licensing formulations was not based on rationality but mostly o_n safety, efficacy and compliance fo_r fixed dos_e of combinations.

The clinical trails of combinations of individual approved drugs were not insisted o_n by the Licensing Authorities in th_e past. There is no clinical trials as such to prove the advantage of such combinations over single drugs.

(e) The names of leading, brands of combinations containing tranquillizers with $vitamin_s$ ^{a}s reported are—Plaei-dox (M/s Lupin); Diazavit (M/s. Gratus Pharma); Diapam Forte (M/s Medwel); Pentapam Forte (M/s. Medwel) Placipam (M/s Adam Pharma) and Fluril (M/s. Medicare).

(f) These formulations are claimed to be useful for th_e treatment of anxiety, tension and certain other psychosomatic disorders.

Overcharging of Rifampicin

2124. SHRl M. KADHARSHA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that certain $Stat_e$ Drug Authorities received compIaints about overcharging the prices ot formulations both based on single ingredient as well as in combination of other drugs of Rifampicin;

(b) whether it is also a fact that certain State Drug Authorities made a survey about the prices;

(c) if so, the details thereof;

(d) what is the price of each formulation based on this drug being charged in Kerala and Delhi by chemists;

(e) whether $thes_e$ prices are higher than the notified prices;

(f) if so, what action was taken against the chemists over-charging th_D prices under Essential Commodity Act; and

(g) what are the names of Chemists where prices were checked?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) t© (g) The information is being collected from the Ministry of Industry (Department of Chemicals and Petrochemicals) and will be laid o_n the Table of the Sabha.